Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 2/20 | 0.31 |
| ▸ | RARG | P13631 | 2/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666701 | 0.86 | ALDH1A1 (0.44) | ALDH1A1GAAMAPTNPSR1ACHE | |
| SCHEMBL10457502 | 0.74 | TRPA1 (0.40) | MAPT | |
| SCHEMBL10457498 | 0.71 | — | — | |
| SCHEMBL4304302 | 0.70 | ALDH1A1 (0.49) | ALDH1A1GAAMAPTNPSR1ACHE | |
| SCHEMBL9484752 | 0.70 | — | — | |
| SCHEMBL10679423 | 0.69 | RARB (0.33) | ALDH1A1RARBRARGRARARXRA | |
| SCHEMBL21523570 | 0.68 | — | — | |
| SCHEMBL9484747 | 0.67 | IDO1 (0.31) | — | |
| SCHEMBL10939855 | 0.67 | ALDH1A1 (0.33) | ALDH1A1MAPT | |
| SCHEMBL16052925 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785178-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20150038574-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2785178-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013081642-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038574-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | ALDH1A1 2346/4885GAA 2480/4885MAPT 1065/4885 |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, PDE6C | ALDH1A1 2346/4885GAA 2480/4885MAPT 1065/4885 |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | ALDH1A1 2346/4885GAA 2480/4885MAPT 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.